文献速递多重用药认知障碍与谵妄

临床医生对美国痴呆老年人中枢神经系统活性多重用药的贡献

Clinician contributions to central nervous system-active polypharmacy among older adults with dementia in the United States.
PubMed 文献 · J Am Geriatr Soc · 2024-11-05

该横断面分析基于2019年Medicare索赔数据,纳入955074名社区居住的痴呆患者,其中14.3%暴露于中枢神经系统活性多重用药。24.6%的患者由单一临床医生开具多重用药,45.3%的多重用药人日由单一医生开具,初级保健医生贡献了63.0%的多重用药人日。

要点

  • 14.3%的社区痴呆患者暴露于中枢神经系统活性多重用药。
  • 45.3%的多重用药人日由单一临床医生开具。
  • 初级保健医生贡献了63.0%的多重用药人日。

核心结论

  • 初级保健临床医生(医生和高级执业提供者)开具了大部分导致痴呆患者中枢神经系统活性多重用药的药物。

研究设计与样本

  • 横断面分析,使用2019年Medicare A、B、D部分索赔数据,纳入955074名社区居住的痴呆患者,主要女性(64.0%)、白人(78.5%),平均年龄83.4岁(标准差8.0)。

主要发现

  • 14.3%的痴呆患者暴露于中枢神经系统活性多重用药(即重叠使用三种或以上中枢神经系统活性药物超过30天)。
  • 在患者层面,24.6%的痴呆患者经历的多重用药由单一临床医生开具。
  • 考虑总暴露天数,45.3%的多重用药人日由单一临床医生开具。
  • 初级保健医生开具了63.0%的多重用药人日,并在所有七类药物的天数中占多数;精神科医生在抗精神病药和苯二氮䓬类中占多数,初级保健高级执业提供者在抗抑郁药和抗癫痫药中占多数。

临床怎么用

  • 关注初级保健医生在痴呆患者中枢神经系统活性多重用药中的核心作用,支持其合理处方。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exposure to central nervous system (CNS)-active polypharmacy-overlapping exposure to three or more CNS-active medications-is potentially harmful yet common among persons living with dementia (PLWD). The extent to which these medications are prescribed to community-dwelling PLWD by individual clinicians versus distributed across multiple prescribers is unclear. METHODS: We identified community-dwelling Medicare beneficiaries with a dementia diagnosis and Medicare Parts A, B, and D coverage for at least one month in 2019. Using fill date and days' supply for prescriptions filled between January 1, 2019 and December 31, 2019, we identified beneficiaries exposed to CNS-active polypharmacy (i.e., >30 days of overlapping exposure to three or more antidepressant, antipsychotic, antiseizure, benzodiazepine, opioid, nonbenzodiazepine benzodiazepine receptor agonists, or skeletal muscle relaxant medications). We examined the number and type of clinicians who contributed to polypharmacy person-days among PLWD. RESULTS: The cohort included 955,074 PLWD who were primarily female (64.0%), were White (78.5%), and had a mean age of 83.4 years (standard deviation 8.0). Notably, 14.3% were exposed to CNS-active polypharmacy. At the person level, 24.6% of PLWD experienced polypharmacy prescribed by a single clinician. Considering total days of exposure, 45.3% of polypharmacy person-days were prescribed by a single clinician. Primary care physicians prescribed 63.0% of polypharmacy person-days and accounted for the plurality of days for all seven medication classes, followed by psychiatrists for antipsychotics and benzodiazepines and primary care advanced practice providers (APPs) for antidepressants and antiseizure medications. CONCLUSION: In this cross-sectional analysis of Medicare claims data, primary care clinicians (both physicians and APPs) prescribed the majority of medications that contributed to CNS-active polypharmacy for PLWD. Future research is needed to identify strategies to support primary care clinicians in appropriate prescribing of CNS-active medications to PLWD.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Vordenberg SE, Davis RC, Strominger J, et al. Clinician contributions to central nervous system-active polypharmacy among older adults with dementia in the United States. J Am Geriatr Soc. 2024. PMID: 39499066. doi:10.1111/jgs.19256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。